Phlow Corporation
Phlow Corporation is a U.S.-based public benefit pharmaceutical manufacturing company dedicated to revolutionizing the production of essential medicines. By leveraging advanced manufacturing processes, Phlow aims to ensure the availability of high-quality, affordable pharmaceuticals and active pharmaceutical ingredients (APIs) domestically. The company is committed to reshoring pharmaceutical manufacturing to the United States, thereby enhancing the nation's healthcare security and reducing dependency on foreign supply chains. Phlow's mission is to provide every American with access to essential medicines, supporting public health and national security. The company also emphasizes sustainability and community engagement, integrating green chemistry and continuous manufacturing to reduce environmental impact and improve the sustainability of pharmaceutical production.
Phlow Corporation
424 Hull St., Suite 400, Richmond, VA 23224
What We Do
Phlow is building the United States’ first Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a national stockpile to secure key ingredients used to manufacture essential medicines on U.S. soil.
Phlow offers contract development and manufacturing organization (CDMO) services that accelerate R&D for APIs and Key Starting Materials while seamlessly scaling up cGMP manufacturing, all within the United States.
Application Area
Key People
Co-Founder, President, and CEO
Chief Scientific Officer
Chief Financial Officer
Vice President of Quality and Regulatory
Strategic Advisor and Member of the Board
News & Updates
Phlow Corp. has earned B Corp certification, continuing its commitment to improve quality, reliability, and access to essential medications.
Phlow Corp. was recognized as one of the world's most innovative companies in 2022 for its efforts in reshoring pharmaceutical manufacturing.
Phlow Corp. has expanded its analytical capabilities and embraced an AI-driven system, ushering in a new era of modern medicine manufacturing in America.
Phlow Corp. completed validation for a novel, cost-competitive epinephrine API process, marking a significant milestone in domestic production.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with Phlow Corporation to provide medical countermeasures.
Phlow participated in the 2023 Continuous Processing Symposium, highlighting advancements in continuous manufacturing processes.